share_log

信達生物：2023年報

INNOVENT BIO: 2023 ANNUAL REPORT

HKEX ·  Apr 29 22:36

Summary by Moomoo AI

信达生物公布了2023年度报告，涵盖截至2023年12月31日的财政年度。报告显示，信达生物是一家专注于肿瘤学、心血管及代谢疾病、自身免疫疾病和眼科等领域生物制药的公司，自2011年成立以来，已与包括礼来、赛诺菲、Incyte、Adimab、LG Chem和MD Anderson癌症中心在内的30多家国际伙伴建立了战略合作关系。产品管线包括36个在研产品，10个已获批上市产品，3个在NMPA审查中的产品，5个分子进入III期或关键临床研究阶段，以及18个处于早期临床研究阶段。公司由于产品销售收入的快速增长、总收入毛利率的提高以及销售、市场营销、行政及其他费用占总收入的比例降低，2023年财务业...展開全部
信达生物公布了2023年度报告，涵盖截至2023年12月31日的财政年度。报告显示，信达生物是一家专注于肿瘤学、心血管及代谢疾病、自身免疫疾病和眼科等领域生物制药的公司，自2011年成立以来，已与包括礼来、赛诺菲、Incyte、Adimab、LG Chem和MD Anderson癌症中心在内的30多家国际伙伴建立了战略合作关系。产品管线包括36个在研产品，10个已获批上市产品，3个在NMPA审查中的产品，5个分子进入III期或关键临床研究阶段，以及18个处于早期临床研究阶段。公司由于产品销售收入的快速增长、总收入毛利率的提高以及销售、市场营销、行政及其他费用占总收入的比例降低，2023年财务业绩显著改善，总收入达到6206.1亿元人民币，同比增长36.2%，产品收入为5728.3亿元人民币，同比增长38.4%，LBITDA减少73.0%至600.1亿元人民币。公司财务状况稳健，现金及短期金融资产约为10969.6亿元人民币。2023年，信达生物将其上市产品组合扩展到10个，其中两个创新产品Fokosu®（Igoleon单克隆注射液）和Xinbile®（Toralexi单克隆注射液）在中国获批上市。公司继续专注于创新癌症治疗，并在临床需求高的多个治疗领域战略定位。信达生物承诺遵循高质量生产标准和企业社会责任，在2023年的MSCI ESG评级中升级至'A'级，在中国制药行业中处于领先地位。
Sinda-Bio has published its 2023 Annual Report, covering the fiscal year ended 31 December 2023. The report shows that Sinda Biologics is a company focused on the field of biopharmaceuticals such as oncology, cardiovascular and metabolic diseases, autoimmune diseases and ophthalmology. Since its inception in 2011, it has established more than 30 international partners including Lai, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Centers Strategic Collaboration. The product pipeline includes 36 products in research, 10 approved marketed products, 3 products under NMPA audit, 5 molecules entering Phase III or pivotal clinical trials, and 18 in the early clinical phase. Due to the rapid growth of product sales revenue, an increase in gross profit margin of gross profit and a decrease in the proportion of total revenue from...Show More
Sinda-Bio has published its 2023 Annual Report, covering the fiscal year ended 31 December 2023. The report shows that Sinda Biologics is a company focused on the field of biopharmaceuticals such as oncology, cardiovascular and metabolic diseases, autoimmune diseases and ophthalmology. Since its inception in 2011, it has established more than 30 international partners including Lai, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Centers Strategic Collaboration. The product pipeline includes 36 products in research, 10 approved marketed products, 3 products under NMPA audit, 5 molecules entering Phase III or pivotal clinical trials, and 18 in the early clinical phase. Due to the rapid growth of product sales revenue, an increase in gross profit margin of gross profit and a decrease in the proportion of total revenue from sales, marketing, administrative and other expenses, the Company's fiscal performance improved in 2023, reaching RMB6206.1, up 36.2% year-on-year, and product revenue of 5728.3 yuan The yuan, up 38.4% year-on-year, and LBITDA decreased 73.0% to 600.1 yuan renminbi. The financial situation of the company is stable, cash and short-term financial assets are approximately 10969.6 RMB. In 2023, SindaBio will expand its portfolio of listed products to 10, of which two innovative products Fokosu® (Igoleon monoclonal injection) and Xinbile® (Toralexi monoclonal injection) will be available in China. The company continues to focus on innovative cancer therapies and strategically focuses on multiple therapeutic areas with high clinical demand. With its commitment to high quality production standards and corporate social responsibility, Sinda Biologics has been upgraded to 'A' level in the MSCI ESG rating in 2023, leading the Chinese pharmaceutical industry.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Latest Price
    HIGHTIDE-B
    02511
    -- 1.300
    EXTRAWELL PHAR
    00858
    -- 0.051
    JACOBSON PHARMA
    02633
    -- 1.050
    C HEALTH GP
    08225
    -- 0.190
    ZHONGZHIPHARM
    03737
    -- 0.990

    Unlock the Full List